ATLANTA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Even though the US cannabis industry continues to make strides toward legal acceptance, 2022 wasn’t a good year for most marijuana stocks, primarily because cannabis companies have failed to turn growth into profits. E-commerce solutions could dramatically impact margins and lower customer acquisition costs.
With the increased adoption of e-commerce by dispensaries and cannabis retailers, the legal marijuana market was valued at $17.50 billion in 2021 and is estimated to reach $80.1 billion by 2031, growing at a CAGR of 16.9% from 2022 to 2031, according to recent research. The main drivers for this expected growth are growing consumer demand, increasing legalizations in various countries and regions, and changing perceptions of cannabis use for medicinal and recreational purposes, with adult use (recreational) comprising 54.6% of the cannabis market.
Multichannel and omnichannel support let cannabis e-commerce websites maintain consistency no matter how a customer interacts with the brand. Creating a unified customer experience is especially important given the requirement for cannabis brands to operate across multiple channels, such as physical stores, different branded e-commerce websites, and government-regulated marketplaces. Privately held Leaflink is one of the leaders in cannabis e-commerce. Leaflink has raised $479 million in funding over eight rounds, with the latest round of $100 million having closed on February 1, 2023.
Cannabis companies that could benefit from the future growth of the cannabis market and e-commerce solutions include: Tilray Brands, Inc. (NASDAQ: TLRY), CannaPharmaRx (OTC Pink: CPMD), Aurora Cannabis, Inc. (NASDAQ: ACB) and Canopy Growth Corporation (NASDAQ: CGC).
Tilray Brands, Inc. (NASDAQ: TLRY) is a global leader in cannabis research, cultivation, processing and distribution. According to its website, Tilray is the first GMP-certified medical cannabis producer to supply cannabis flower and extract products to tens of thousands of patients, physicians, pharmacies, hospitals, governments and researchers on five continents.
For the second fiscal quarter ending November 30, 2022, Tilray's gross profit rose to $40.1 million, a 22% increase, year over year, while adjusted gross margin held at 29% compared to the year-ago quarter. Tilray's gross profit on cannabis increased 37% to $18.6 million from $13.5 million in the prior year quarter, while the gross margin percentage increased to 37% from 23%. Tilray had adjusted EBITDA of $11.7 million, marking the 15th consecutive quarter of positive adjusted EBITDA.
CannaPharmaRx (OTC Pink: CPMD) is focused on acquiring and developing state-of-the-art cannabis grow facilities in Canada. CannaPharmaRx recently announced it added to its revenue stream by purchasing the e-commerce and financial platform LTB Management. LTB has direct experience developing online website applications for various customers, including medical cannabis deliveries for pharmacies, distributors, and producers on an international scale. According to a recent press release, this acquisition will augment CannaPharmaRx's anticipated cannabis sales, which the company expects to produce and deliver at an annual run rate of nearly $30 million.
During 2023 CannaPharmaRx plans to further accelerate its E-commerce applications. The company plans to complete its first harvest during Q1 2023 and additional offtake agreements in multiple countries.
Aurora Cannabis (NASDAQ: ACB) is an Edmonton, Alberta-based cannabis company serving the medical and consumer markets. Aurora's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, Greybeard, and CBD brands, Reliva and KG7. Medical cannabis brands include MedReleaf, CanniMed, Aurora, and Whistler Medical Marijuana Co. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants.
Aurora recently posted revenues of $50.95 million for its second quarter that ended December 31, 2022, versus revenues of $48.07 million. The company had a quarterly loss of $0.14 per share versus a loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items. The current consensus EPS estimate is -$0.06 on $48.38 million in revenues for the coming quarter and -$0.34 on $176.58 million in revenues for the current fiscal year.
Canopy Growth Corporation (NASDAQ: CGC) is a North American cannabis and consumer packaged goods company focusing on premium and mainstream cannabis brands including Doja, 7ACRES, Tweed, and Deep Space. Its CPG portfolio features sugar-free sports hydration brand BioSteel, targeted 24-hour skincare and wellness solutions from This Works, gourmet wellness products by Martha Stewart CBD, and category defining vaporizer technology made in Germany by Storz & Bickel. Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through its rights to Acreage Holdings, Wana Brands, and Jetty Extracts.
Canopy Growth recently announced net revenue of $101 million for the third quarter of its 2023 fiscal year, a 28% decline from the same quarter in fiscal 2022. The company posted a net loss in Q3 FY2023 of $267 million, which was a $151 million increase from Q3 FY2022. Company Growth announced a cost reduction program of $140-$160 million over the next 12 months.
About OTC Stock Review
Since 2004, OTC Stock Review has provided a free service introducing thousands of traders to some of the best companies in the microcap sector. Our alerts consist of Nasdaq, NYSE, and high-quality OTC companies with full disclosure on compensation and ownership.
Our custom company profiles can help create volume in seemingly unnoticed stocks. By getting new eyeballs on your company, important company news releases could have even more impact and bring the profiled company into the spotlight of the general investment community. This solid foundation and raised awareness can have a positive effect on all shareholders, as well as provide a more liquid market for the company’s stock. If you are interested in the lucrative microcap sector, sign up for OTC Stock Review today!
DISCLAIMER: Atlanta Capital Partners, LLC (ATLCP), which owns and operates Otcstockreview.com, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. ATLCP is NOT affiliated in any manner with any company mentioned herein. ATLCP and its affiliated companies are news dissemination solutions providers and are not a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. ATLCP’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is never to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. ATLCP is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed ATLCP was compensated three thousand five hundred dollars for news coverage of current press releases issued by CannaPharmaRx, Inc. ATLCP holds no shares of any company named in this release.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and ATLCP undertakes no obligation to update such statements.
Contact:
OTC Stock Review
David Kugelman
(866) 692-6847
dk@otcstockreview.com
https://otcstockreview.com
